BACKGROUND: Morbidly obese patients enrolled in a rapid weight reduction program are at a high risk of developing gallstones. Two multicenter, placebo-controlled, randomized, double-blind trials have demonstrated that the prophylactic use of ursodiol in males and femals 18 to 70 years of age is effective for the prevention of gallstone formation in this patient population. This study examines the cost consequences associated with the prophylactic use of ursodiol. METHODS: A medical decision analysis model for the prophylactic administration of ursodiol in morbidly obese patients undergoing rapid weight reduction by either gastric bypass surgery or very-low-calorie-diet, was developed through the use of data from two clinical trials and review of the related literature. The expert opinion of clinicians from the ®elds of internal medicine, gastroenterology and surgery were solicited. Financial data for the charges associated with cholecystectomies, physician fees and ursodiol were obtained from current ®nancial databases. RESULTS: The model demonstrates that the prophylactic administration of ursodiol, in morbidly obese patients undergoing rapid weight reduction, results in cost savings. Sensitivity analysis was performed to illustrate that the cost savings achieved by the prophylactic use of ursodiol were valid over a realistic range of charges and assumptions. CONCLUSION: The decision model may allow health care decision makers to apply their own data to the model to determine the cost savings obtainable through the prophylactic use of ursodiol in patients undergoing rapid weight reduction.
Introduction
Gallstone disease is a serious medical problem in the US. Approximately 10±15% of the general adult population, or more than 25 million people in the US, have gallstones. It is estimated that one million new cases are diagnosed annually. 1 Although most individuals with gallstones are asymptomatic, 2 the number of cholecystectomies annually performed in the US, for treatment of symptomatic gallstones and their complications, is greater than 571 000, 3 making cholecystectomy the most common elective abdominal surgical procedure. 4, 5 Wolf and Colditz 6 reported that in 1994 the direct costs associated with gallbladder disease were $8.0 billion. The prevention of gallstone formation would, therefore, be expected to have major cost saving implications.
Gallstones form when the constituents of the gallbladder bile come out of solution. Once these gallstones are present, they may grow, shrink or remain at the same size for many years. New stones may develop, while existing stones may dissolve or be passed. Gallstones may cause no symptoms (silent) or they can produce biliary pain by blocking the cystic or common bile ducts.Someof the short andlongterm complications of gallstones include: cholecystitis, perforation of gallbladder, gallstone ileus, jaundice, cholangitis, pancreatitis, and carcinoma of the gallbladder. 7 A range of risk factors for developing gallstones has been identi®ed, including: obesity, multiple pregnancies, female gender, total parenteral nutrition and old age. 1, 8 Morbidly obese patients enrolled in a rapid weight reduction program are at a high risk of developing gallstones, especially during the ®rst two years after completing the weight reduction program. Stampfer et al 9 observed a seven-fold excess risk for symptomatic gallstones in women with a body mass index (BMI) b45 kg/m 2 compared with those whose BMI was`24 kg/m 2 . Ursodeoxycholic acid (ursodiol; Actigall, CibaGeigy, Summit, New Jersey, USA) is a naturally occurring bile salt that increases cholesterol solubility and reduces cholesterol secretion into the bile. It has been used as a gallstone dissolution agent 10±12 and approved by the Food and Drug Administration (FDA) for that indication. Previous studies have indicated that ursodeoxycholic acid could reduce the incidence of gallstone formation in patients undergoing rapid weight reduction, by either very-low-calorie diet 13 or bariatric surgery. 14 These observations led to two multicenter, placebo-controlled, randomized, double-blind trials to determine the optimal dosage of ursodiol to prevent gallstone formation in patients undergoing either gastricbypass-induced 12 rapid weight loss (b300 patients) or very-low-calorie-diet 11 weight loss (b1000 patients). The results of these two trials indicate that the prophylactic use of ursodiol is effective in preventing gallstone formation in patients undergoing rapid weight reduction. These trials served as the basis for the FDA to approve this new indication for ursodiol.
Methods
This paper describes the medical decision analysis model that has been developed to estimate the cost savings obtainable via the prophylactic use of ursodiol to prevent gallstone formation in morbidly obese patients undergoing rapid weight loss and to document those savings. The model incorporates both clinical and ®nancial data in a decision tree. Expert opinion of clinicians from the ®elds of internal medicine, gastroenterology and surgery at Thomas Jefferson University Hospital, Philadelphia, USA were obtained with respect to the development of the model. The ®nancial data incorporated in the model were obtained from the University Health System Consortium (UHC) aggregate discharge data, 15 which contains detailed 1993 charge data for all Diagnosis Related Groups (DRGs) for UHC member hospitals, the 1995 edition of the Drug Topics Red Book 16 and the 1995 edition of the Physicians Fee and Coding Guide.
17 Data 2.6, software available from TreeAge Software Inc., 18 was used to develop the decision analysis tree.
The structure of the analysis initially follows the clinical endpoint of the ursodiol randomized controlled clinical trials that were submitted to the FDA. 11, 12 The clinical endpoint of interest in both trials was the formation of a gallstone (see Figure 1 and Figure 2 ). From this endpoint (namely, gallstone formation), clinical data from a thorough review of the published literature was incorporated into the model. Literature review allowed for estimations regarding the presence of symptoms associated with gallstones (symptomatic vs asymptomatic gallstones), severity of symptomatic gallstones and course of treatment (medication vs surgery). The model does not allow for changes in symptomatic state or changes in severity. A one-year time frame was chosen for the model. Nevertheless, it is established that the risk of surgery extends beyond one year from gallstone formation. Both of these constraints were used to simplify the analysis. Due to this time frame, discounting was not needed. The model assumes the perspective of a payer; therefore, only costs associated with the treatment of gallstones and the prophylactic use of ursodiol were considered.
Decision tree
Using Data 2.6 18 , two decision tree models were developed, based on the clinical trials for the gastric bypass surgery 12 trial and the VLCD 11 trial. Results from the trials are summarized in Figure 1 and Figure  2 .
Data from the clinical trials did not provide information regarding the number of patients who developed symptoms which required medical management. Using data collected from the published literature and with the aid of expert consultants, a decision tree, which follows these patients for a period of one year from completion of the weight reduction program, was developed. A one-year time frame was adopted because all the costs associated with ursodiol prophylaxis are accrued within the ®rst few months of therapy and these patients are at highest risk of developing Prevention of gallstones O Shoheiber et al cholecystitis within the ®rst year following weight loss. Any cost-effectiveness ®ndings associated with ursodiol use in the ®rst year, will not be affected by extending the time frame for following these patients beyond the ®rst year. It was also felt that the importance of developing a simple, reproducible tree, which could be utilized by interested individuals in their decision making analysis, to estimate the potential savings or added costs associated with the`use' or`no use' of ursodiol, in the medical management of obesity, would be better served with a one-year time frame.
The next step in the development of the decision tree was to estimate the percentage of patients with gallstones that would become symptomatic. Other studies published in the medical literature reported a range of 20±40% for the incidence of gallstone formation in morbidly obese patients undergoing rapid weight loss, 13, 14, 22 right in line with the results obtained in the placebo arms of the two trials being investigated. Two of these studies also relied on abdominal ultrasonography to detect gallstones. Many of the stones detected would be asymptomatic and disappear spontaneously. Only a percentage of the stones detected would become symptomatic and require therapy. There are, however, three recently published studies that reported the percentage of patients undergoing rapid weight loss, who developed symptomatic gallstones.
22±24
Shiffman et al, 22 Deitel and Petrov, 23 and Kamrath et al 24 reported in three different studies that 16.0% (13 out of 81 patients developed symptomatic gallstones within six months post-gastric bypass surgery), 11.5% (39 out of 339 patients developed symptomatic gallstones post-bariatric surgery, 17 in year one, 17 in year two and 5 in years 3±12) and 10.3% (15 out of 146 patients developed symptomatic gallstones during, or within six months of completing, a VLCD program) of their patients, respectively, developed symptomatic gallstones after rapid weight loss. Older published literature had indicated that about 20±40% of stones, developing as a result of rapid weight loss, would become symptomatic and would require medical intervention. In this decision model, it was estimated that approximately 25% of the stones detected using ultrasonography, would become symptomatic during a one-year period. This results in 7% of the non-ursodiol patients in the very-low-caloriediet trial and 8% of the no-ursodiol patients in the gastric bypass surgery trial, developing symptomatic gallstones. These are relatively conservative estimates (7% and 8%) when compared to the percentages reported by Shiffman et al, 22 Deitel and Petrov, 23 and Kamrath et al.
24
The next step determined the percentage of patients with symptomatic gallstones that would require surgical removal vs medical management. There were numerous sporadic reports in the literature regarding the percentage of gallstones requiring surgical removal. Broom®eld et al, 13 reported that 5.2% of their patient cohort required surgery within one year. Kamrath et al, 24 reported that 5.5% of their cohort needed surgery, while Shiffman et al 22 and Worobetz et al 14 reported 11% and 14%, respectively. In another study, Shiffman et al 25 reported a 10% incidence of surgery over a two-year period, while Deitel and Petrov 22 reported a 5% surgery incidence in year one and another 5% in year two, post bariatric surgery.
In this decision tree, it was assumed that 65% of all symptomatic gallstones would require surgical removal. This necessitates that 4.5% of the no-Ursodiol patients in the VLCD trial and 5.2% of the noUrsodiol patients in the gastric bypass surgery trial would require surgery. One can ®nd, that these are also conservative estimates of the ultimate percentage of patients who will require cholecystectomies within a one-year period of completing a weight reduction program, when compared to the above literature data.
The number of cholecystectomies to be performed via open surgery or laparoscopically was also estimated. Surgical removal of gallstones can be accomplished via either a laparoscopic cholecystectomy or an open cholecystectomy. Laparoscopic cholecystectomy is a relatively new procedure, less than ten years old, yet it is the procedure of choice for most physicians and patients. This procedure has a success rate and safety pro®le comparable to that for open surgery. Laparoscopic surgery requires fewer days of hospitalization and is associated with shorter morbidity. In the general population, up to 95% of gallstones can be removed laparoscopically. 26 Until recently, obesity was considered a contraindication for laparoscopic cholecystectomy. Surgeons at Thomas Jefferson University Hospital now believe that obesity is no longer a contraindication and up to 90% of obese patients can be operated on laparoscopically, due to surgeons' improved pro®-ciency with the procedure. When questioned about operating on patients within 6±18 months of undergoing gastric bypass surgery, they said that only about 50% of these patients would be candidates for a laparoscopic procedure. 27, 28 Therefore, the VLCD model assumed 90% of the patients requiring surgery would undergo laparoscopic surgery (10% open surgery) and the gastric-bypass model assumed that patients requiring surgery would be split evenly (50% each) between laparoscopic and open surgery.
Patients with symptomatic gallstones who do not undergo cholecystectomy are usually managed medically. 29, 30 These patients usually present mild symptoms and are usually closely monitored by physicians. The majority of these patients are given oral ursodiol therapy (8±12 mg/kg/d) for approximately 12 months. In this analysis we assumed that all patients who are symptomatic and do not undergo a cholecystectomy will receive a 12 month therapy of a daily dose of 900 mg/d ursodiol. Patients on oral ursodiol therapy would be managed by physicians. Since we could ®nd no good information on whether these patients would be managed by a generalist or a specialist and could not estimate the number of visits these patients would make to their physicians over a one-year period, it was decided not to make any assumptions regarding these issues. Due to the higher incidence of gallstones in the no-ursodiol arms of both decision models, ignoring of®ce visits for these patients would have a greater impact on the no-ursodiol arms of the models. If the costs of these visits were included, the overall impact would be a larger increase in the cost of the noursodiol arms of the model.
Using all this information (including the assumptions discussed above) the decision trees for gastric bypass surgery (Figure 3 ) and the VLCD (Figure 4) were constructed. The probabilities at each branch point were assigned and then the costs associated with each terminal were determined. The costs used in the two decision trees is summarized in Table 1 . 
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Clinical data
Details regarding the clinical trials that were sponsored by Ciba-Geigy, Summit, NJ, USA, and their results can be obtained from the published literature articles of Shiffman et al 11 and Sugerman et al. 12 Both trials determined that the optimum dose to prevent gallstone formation was 600 mg/d. The ®ndings associated with the 600 mg/d dose are as follows. In the very-low-calorie diet (VLCD), patients who were treated with 600 mg/d for a 16 week period, while consuming a 524 kcal/d liquid protein diet, had an incidence rate of gallstone formation of 3% (7 of 201 patients) compared to 28% (57 of 202 patients) of the placebo group. In the gastric bypass surgery trial, patients receiving a 600 mg/d ursodiol dose beginning within 10 d after gastric bypass surgery and continuing for six months, had an incidence rate of 2% (1 of 61 patients) vs 32% (18 of 56 patients) of the placebo group.
Costs
Costs incorporated into the decision tree include prices for the following items: a 300 mg capsule of ursodiol, hospital charges for open and laparoscopic cholecystectomy and physician fees (namely the surgeon and the anesthesiologist) for open and laparoscopic cholecystectomy. The values were obtained from a variety of sources (vide infra) and were not adjusted for in¯ation to obtain a base year.
The average wholesale price (AWP) of ursodiol was obtained from the 1995 edition of the Drug Topics Red Book 16 where the price was reported to be $2.07 per 300 mg capsule. Hospital charge data for open and laparoscopic cholecystectomy were obtained from the University Health System Consortium (UHC) Information Network. Aggregate discharge data for all UHC member hospitals related to Diagnosis Related Groups (DRGs) 197 and 198 (total cholecystectomy without common duct exploration, with or without complications and co-morbidities) were used to estimate charges associated with open (DRG 197) and laparoscopic (DRG 198) cholecystectomy. 15 This data represents charges for the above DRGs for the calendar year of 1993 (Table 2) . Physician fees were obtained from the 1995 edition of the Physicians Fee and Coding Guide. 17 Surgeon fees for open and laparoscopic cholecystectomy (CPT codes 47600 and 56340) range between $1859±2959. Anesthetist fees for upper abdominal procedures including laparoscopy (CPT code 00790) range between $236±725. A combined average physician fee of $2890 was used in the analysis ((1859 2959)/ 2 (236 725)/2). Costs associated with adverse drug reactions due to the use of ursodiol, and complications with open and laparoscopic surgery were not considered in the model. Ursodiol-related drug reactions were not included in this study because they are very minimal and their incidence is similar to placebo. 10, 19 Ursodiolrelated drug reactions include: nausea, vomiting, constipation, rash, sweating and headache. Their low incidence and mild nature have a diminished impact on the cost associated with the use of ursodiol.
Complications associated with open and laparoscopic surgery are reported to be 1±2% in the general population. 20, 21 It can be argued that morbidly obese patients are at higher risk for complications compared to the general population. Including costs for surgical complications in this analysis would have a bigger impact on the placebo arm, thus favoring ursodiol. The costs of these surgical complications were not included in this model, because their inclusion would affect the magnitude of the difference in the two treatment arms, but does not change the preferred treatment indicated by the model.
Analysis
Utilizing Data 2.6, the costs associated with choosing the ursodiol branch vs the no-ursodiol branch were calculated ( Figure 3 and Figure 4 ). The software starts at the terminus of each branch (denoted by the triangle) and`rolls back' (that is, takes the costs associated with each terminus and multiplies them by the probability of the branch associated with that terminus, to determine the costs at each node in the tree) the analysis to determine the costs associated with traveling down either the ursodiol or no-ursodiol branches.
The analysis of the VLCD analysis tree estimates the cost savings associated with the use of prophylactic ursodiol (ursodiol branch $539 vs no-ursodiol branch $696). In the same fashion, the gastricbypass surgery decision model estimated that the cost of the ursodiol arm was $809 vs $1019 for the placebo arm. 
Sensitivity analysis
When the values used in the decision tree are estimates of the actual values, sensitivity analysis is typically performed. By varying the estimated costs and probabilities of the branches within an acceptable range, changes in the results of the analysis can be detected. In this manner, one can determine the critical parameters in the model (threshold values). Sensitivity analyses were conducted on the costs of laparoscopic cholecystectomy, open cholecystectomy, ursodiol and the physician fees. The probability of symptomatic stones requiring surgery was also varied ( Table 3 ). The cost of laparoscopic cholecystectomy was varied between $5000 and $15 000. In the gastric bypass tree, this did not change the outcome of the analysis. In the VLCD tree however, as long as the cost of laparoscopic cholecystectomy is greater than $5800, the management of obese patients who are on very-low-calorie diets is less expensive, if they are treated prophylactically with ursodiol.
The cost of open cholecystectomy was varied between $5000 and $25 000. In the gastric bypass surgery tree the no-ursodiol branch becomes favored as the cost of open cholecystectomy falls below $12 230. The VLCD model was not sensitive to the cost of an open cholecystectomy; therefore, the use of ursodiol was always preferred.
Sensitivity analysis was also performed on the combined surgeon and anesthetist physician fees. The analysis demonstrated that varying the physician fees between $500 and $3500, does not change the outcome of either decision tree, namely that the use of ursodiol was always the preferred pathway. In other words, the models are not sensitive to changes in physician fees.
The cost of a single 300 mg dose of ursodiol was ranged at $1.50±3.50. These analyses demonstrated that as long as the cost of a 300 mg dose is below $2.70 in the gastric bypass decision model, and below $2.86 in the very-low-calorie-diet model, then ursodiol prophylaxis is favored. Not using ursodiol prophylactically, only becomes favored when the cost of a 300 mg dose rises above these two values. The cost of a 300 mg dose in these models was ursodiol's AWP of $2.07, well below the value in either model, where a change is seen.
The probability of undergoing surgery among patients who developed symptomatic gallstones was analyzed (Table 3) . By varying this probability, the percentage of patients undergoing surgery (both open and laparoscopic) varies due to the constraints placed on the model from the literature review (vide supra).
In the gastric bypass model, the no-ursodiol arm only becomes favorable if the probability of surgery among symptomatic patients drops below 48%. In the verylow-calorie-diet model, as long as the probability of surgery for these patients is greater than 44%, prevention with ursodiol is favored. These results mean that 3.8% and 3.1% of the no-ursodiol patients in the gastric bypass and VLCD models, respectively, would require cholecystectomies. Our assumption is that the probability of surgery was 65% among symptomatic patients (that is, 5.2% and 4.5% of all patients in both models, respectively, will require surgery). As mentioned earlier, previous studies have found surgical rates b5% for these patient populations.
13,22±25
Two-way sensitivity analysis was conducted on the costs of laparoscopic and open cholecystectomy. The hospital charges for these two procedures, $10 121 and $20 836, respectively, were found to be well within the zone where the use of ursodiol was favored in both models ( Figure 5 and Figure 6 ).
Discussion
The results of this decision analysis model, estimate the cost savings associated with the use of ursodiol in the prevention of gallstone formation in obese patients undergoing rapid weight loss. The model developed in this study incorporates data from clinical trials, a variety of published studies, expert opinions and charge data. Charges and probabilities used in this analysis were conservative. The model was not designed to provide the exact costs associated with the management of obese patients undergoing rapid weight loss. The sensitivity analyses performed, illustrate that the cost savings associated with the use of ursodiol in obese patients undergoing rapid weight loss, are valid over a range of charges and probabilities. Although many of the assumptions made in this model are time and location dependent, the methodological approach is easily reproducible, enabling policy makers to apply this analysis locally. One concern that a decision maker may have, was the use of hospital charge data for estimating the amount payers would reimburse for open and laparoscopic cholecystectomies. A decision maker may also be concerned with the appropriateness of using aggregate charge data from academic medical centers. The sensitivity analyses indicate that both these concerns are unwarranted. Klar 32 Our sensitivity analysis on the charges for laparoscopic and open surgeries needs to be examine in light of these amounts. In the gastric bypass model, the outcome of the analysis was unchanged by varying the charge for laparoscopic surgery between $5000±15 000, the preventative use of ursodiol was always the preferred pathway. However, in the VLCD tree, the no-ursodiol branch became favored when the charge for laparoscopic surgery dropped below $5800. Adding the physician fees to this charge ($2890 $5800) gives a total charge of treatment of $8690. This amount ($8690) is over $1100 less than the amount that BCBSNCA reimburses ($9792) for laparoscopic surgery. The results for open surgery are also very similar. In the VLCD model, ranging the charge of open surgery between $5000±25 000 has no impact on the outcome of the analysis, the ursodiol branch is always favored. In the gastric bypass surgery model, however, the no-ursodiol branch only becomes favored when the charge for open surgery falls below $12 230. In other words, when the total charges for open surgery (physician fees and hospital charges) are less than $15 120 ($2890 $12 230), the no-ursodiol branch becomes favored. This amount ($15 120) is also over $1100 less than the amount BCBSNCA reimburses ($16 264) for open surgery.
As mentioned earlier, female gender and multiple pregnancies are important risk factors in developing gallstones. When estimating the costs of rapid weight loss in the study population, consideration should be given to the increased risk that females are at, for developing gallstones. In the VLCD study, slightly more females (30%) than males (25%), who received placebo, developed gallstones. There were no differences seen in the incidence of gallstone formation in the gastric bypass study. Ursodiol prophylaxis was found to be equally effective in preventing gallstone formation in males and females. There were no differences in gallstone formation observed between the sexes in any of the treatment arms. Due to a lack of differences in gallstone formation between the sexes in either of the treatment arms, the model was not tested separately in men and women. In the lowcalorie-diet study, where slightly more females than males developed gallstones in the placebo arm, analysis of the model by gender, would have resulted in an even greater advantage for the use of ursodiol in female patients. Simply stated, the model was not sensitive to the gender of the patients.
The above analyses estimates that ursodiol prophylactic treatment, in patients undergoing rapid weight reduction, results in cost savings under current reimbursement scenarios for cholecystectomies. Gallstone formation in obese patients undergoing rapid weight reduction, is both a medical risk and a cost that should be minimized. We believe that our decision analysis model will assist health care decision makers in applying their own data to estimate the cost savings obtainable by the prophylactic use of ursodiol in this patient population.
